Role of conventional treatments on circulating and monocyte-derived dendritic cells in colorectal cancer

被引:36
作者
Bellik, Lydia
Gerlini, Gianni
Parenti, Astrid
Ledda, Fabrizio
Pimpinelli, Nicola
Neri, Bruno
Pantalone, Desiree
机构
[1] Univ Florence, Dept Crit Med & Surg, I-50139 Florence, Italy
[2] Univ Florence, Dept Preclin & Clin Pharmacol, Lab Vasc Pharmacol, I-50139 Florence, Italy
[3] Univ Florence, Dept Dermatol Sci, I-50139 Florence, Italy
[4] Univ Florence, Oncol Day Hosp, Dept Internal Med, I-50139 Florence, Italy
关键词
human dendritic cells; BDCA subsets; colorectal cancer; conventional treatments; immunotherapy;
D O I
10.1016/j.clim.2006.06.011
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 [免疫学];
摘要
We investigated the effects of metastasis, surgery and chemotherapy on both circulating dendritic cells (DCs) and monocyte-derived-DCs (MoDCs) in colorectal cancer (CRC) patients. Metastatic or nonmetastatic CRC patients had significantly reduced DC subsets compared to healthy subjects (p < 0.001). These cells were significantly higher in metastatic than in nonmetastatic patients. MoDCs were significantly tower in metastatic than healthy and nonmetastatic subjects (p < 0.001). Surgically treated patients had nearly one-half circulating DC subsets compared to healthy subjects (p < 0.001) while no difference was found between unoperated and healthy subjects. MoDCs obtained from tumor-bearing were significantly higher than in operated subjects. In both cases, MoDCs were significantly tower than in healthy subjects (p < 0.001). Circulating DCs and MoDCs were significantly lower in CRC patients, with or without chemotherapy, compared to healthy subjects (p < 0.001). Compared to untreated, chemotherapy-treated patients had 30% fewer DC subsets and tower MoDCs. Characterization of circulating DC subsets and MoDCs may elucidate CRC patients' immune system status. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:74 / 80
页数:7
相关论文
共 29 条
[1]
Almand B, 2000, CLIN CANCER RES, V6, P1755
[2]
Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen [J].
André, T ;
Bensmaine, MA ;
Louvet, C ;
François, E ;
Lucas, V ;
Desseigne, F ;
Beerblock, K ;
Bouché, O ;
Carola, E ;
Merrouche, Y ;
Morvan, F ;
Dupon-André, G ;
de Gramont, A .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (11) :3560-3568
[3]
Dendritic cells as therapeutic vaccines against cancer [J].
Banchereau, J ;
Palucka, AK .
NATURE REVIEWS IMMUNOLOGY, 2005, 5 (04) :296-306
[4]
Brivio F, 2000, HEPATO-GASTROENTEROL, V47, P1337
[5]
The immunogenicity of dendritic cell-based vaccines is not hampered by doxorubicin and melphalan administration [J].
Casati, A ;
Zimmermann, VS ;
Benigni, F ;
Bertilaccio, MTS ;
Bellone, M ;
Mondino, A .
JOURNAL OF IMMUNOLOGY, 2005, 174 (06) :3317-3325
[6]
Dendritic cell-based cancer immunotherapy: Potential for treatment of colorectal cancer? [J].
Chen, WX ;
Rains, N ;
Young, D ;
Stubbs, RS .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2000, 15 (07) :698-705
[7]
BDCA-2, BDCA-3 and BDCA-4: Three markers for distinct subsets of dendritic cells in human peripheral blood [J].
Dzionek, A ;
Fuchs, A ;
Schmidt, P ;
Cremer, S ;
Zysk, M ;
Miltenyi, S ;
Buck, DW ;
Schmitz, J .
JOURNAL OF IMMUNOLOGY, 2000, 165 (11) :6037-6046
[8]
Dendritic cells in antitumor immune responses .2. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors [J].
Gabrilovich, DI ;
Nadaf, S ;
Corak, J ;
Berzofsky, JA ;
Carbone, DP .
CELLULAR IMMUNOLOGY, 1996, 170 (01) :111-119
[9]
Metastatic melanoma secreted IL-10 down-regulates CD1 molecules on dendritic cells in metastatic tumor lesions [J].
Gerlini, G ;
Tun-Kyi, A ;
Dudli, C ;
Burg, G ;
Pimpinelli, N ;
Nestle, FO .
AMERICAN JOURNAL OF PATHOLOGY, 2004, 165 (06) :1853-1863
[10]
Dysfunctional regulation of the development of monocyte-derived dendritic cells in cancer patients [J].
Hasebe, H ;
Nagayama, H ;
Sato, K ;
Enomoto, M ;
Takeda, Y ;
Takahashi, TA ;
Hasumi, K ;
Eriguchi, M .
BIOMEDICINE & PHARMACOTHERAPY, 2000, 54 (06) :291-298